A number of approaches aimed at reducing myostatin action for the treatment of muscular dystrophies have already been considered, including gene therapy by delivery of myostatin-inhibiting genes, propeptide or small-interfering RNA using AAV or retrovirus (12, 18, 57), administration of antimyostatin blocking antibodies (52) or ActRIIB competitors (1, 14, 36, 59), and antisense oligonucleotide-mediated exon skipping (22, 23). This evidence concerns the gene ACVR2B and muscular dystrophy.